TGF Beta receptor biology in human renal cell carcinoma
TGF Beta receptor biology in human renal cell carcinoma
批准号:
6822693
负责人:
John A. Copland
金额:
$30.68万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2004
资助国家:
美国
项目状态:
已结题
起止时间:
2004-08-10 至 2009-07-31
关键词:
Adenoviridaeathymic mousebiological signal transductioncarcinogenesiscell lineclinical researchgene deletion mutationgene therapygenetic promoter elementgenetic regulationgenetic transcriptiongrowth factor receptorshuman tissuemetastasismolecular oncologyneoplasm /cancer geneticsnonhuman therapy evaluationpoint mutationprotein protein interactionprotein structure functionreceptor expressionrenal cell carcinomatranscription factortransfection /expression vectortransforming growth factors
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Renal cell carcinoma (RCC) is a major health issue. While localized disease can be cured surgically, there is no effective treatment for metastatic disease. The development of therapy awaits understanding of the molecular pathways that underlie RCC carcinogenesis. Using genomic profiling of conventional RCC patient matched specimens, we identified aberrations in the transforming growth factor beta (TGFbeta) pathway. We observed loss of type III TGFbeta receptor (TbetaR3) in all samples. This suggests that loss of TbetaR3 is an early, sentinel event in the genesis of RCC. This is the first clear demonstration linking loss of TbetaR3 to a disease state. We also observed loss of type II TGFbeta receptor (TbetaR2) in metastatic RCC's. These data suggest that aberrations in TGFbeta signaling are important in RCC carcinogenesis and progression, and are mediated through down regulation of TbetaR. We hypothesize that loss of TbetaR3 promotes RCC tumorigenesis through dysregulation of TGFbeta signaling, mediated through Smad dependent and/or independent mechanisms. Our preliminary data also support the hypothesis that TbetaR3 has growth inhibitory activity independent of TGFbeta signaling and TbetaR2. These hypotheses will be tested in models of RCC, in vitro and in vivo, through the following specific aims: 1) We will test the hypothesis that TbetaR3 inhibits cell proliferation in RCC, in vitro, through both Smad dependent and independent mechanisms. We will further test whether TbetaR3 growth inhibition is mediated through TGFbeta/TbetaR2 independent pathways through interaction with, as yet, unknown intracellular proteins. 2) We will test the hypothesis that TbetaR3 inhibits tumorigenicity in vivo, using relevant animal models of RCC. We will test the efficacy of adenoviral gene therapy targeting TbetaR. 3) We will test the hypothesis that TbetaR3 is silenced in RCC through transcriptional regulation of the TbetaR3 promoter. Completion of these studies will define the role of TbetaR3 loss in RCC carcinogenesis, the function of TbetaR3 in normal renal biology and carcinogenesis, and the mechanism of regulation of TbetaR3 in RCC biology.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Modulation of cancer induced immune suppression via inhibition of SCD1
-
批准号:10896572
-
项目类别:
-
资助金额:$130.18万
-
财政年份:2022
-
负责人:John A. Copland
-
依托单位:
Modulation of cancer induced immune suppression via inhibition of SCD1
-
批准号:10546697
-
项目类别:
-
资助金额:$40.0万
-
财政年份:2022
-
负责人:John A. Copland
-
依托单位:
Engineered microtumor arrays for development of combination therapies
-
批准号:10029690
-
项目类别:
-
资助金额:$24.39万
-
财政年份:2020
-
负责人:John A. Copland
-
依托单位:
Engineered microtumor arrays for development of combination therapies
-
批准号:10442587
-
项目类别:
-
资助金额:$26.01万
-
财政年份:2020
-
负责人:John A. Copland
-
依托单位:
Engineered microtumor arrays for development of combination therapies
-
批准号:10667422
-
项目类别:
-
资助金额:$14.59万
-
财政年份:2020
-
负责人:John A. Copland
-
依托单位:
Engineered microtumor arrays for development of combination therapies
-
批准号:10259730
-
项目类别:
-
资助金额:$24.19万
-
财政年份:2020
-
负责人:John A. Copland
-
依托单位:
Osteopontin-targeted therapy for primary CNS lymphoma
-
批准号:9342631
-
项目类别:
-
资助金额:$28.4万
-
财政年份:2017
-
负责人:John A. Copland
-
依托单位:
Novel SCD1 inhibitors for treatment of cancer
-
批准号:9768370
-
项目类别:
-
资助金额:$123.68万
-
财政年份:2016
-
负责人:John A. Copland
-
依托单位:
Novel SCD1 inhibitors for treatment of cancer
-
批准号:9048181
-
项目类别:
-
资助金额:$27.9万
-
财政年份:2016
-
负责人:John A. Copland
-
依托单位:
RhoB in cancer pathogenesis and as a target in combinatorial therapy
-
批准号:8458908
-
项目类别:
-
资助金额:$29.37万
-
财政年份:2010
-
负责人:John A. Copland
-
依托单位:
RhoB in cancer pathogenesis and as a target in combinatorial therapy
-
批准号:8080445
-
项目类别:
-
资助金额:$31.24万
-
财政年份:2010
-
负责人:John A. Copland
-
依托单位:
RhoB in cancer pathogenesis and as a target in combinatorial therapy
-
批准号:7889545
-
项目类别:
-
资助金额:$33.58万
-
财政年份:2010
-
负责人:John A. Copland
-
依托单位:
RhoB in cancer pathogenesis and as a target in combinatorial therapy
-
批准号:8250472
-
项目类别:
-
资助金额:$31.24万
-
财政年份:2010
-
负责人:John A. Copland
-
依托单位:
RhoB in cancer pathogenesis and as a target in combinatorial therapy
-
批准号:8657846
-
项目类别:
-
资助金额:$30.3万
-
财政年份:2010
-
负责人:John A. Copland
-
依托单位:
TGF Beta receptor biology in human renal cell carcinoma
-
批准号:7911288
-
项目类别:
-
资助金额:$15.29万
-
财政年份:2009
-
负责人:John A. Copland
-
依托单位:
TGF Beta receptor biology in human renal cell carcinoma
-
批准号:6933036
-
项目类别:
-
资助金额:$25.25万
-
财政年份:2004
-
负责人:John A. Copland
-
依托单位:
TGF Beta receptor biology in human renal cell carcinoma
-
批准号:7111717
-
项目类别:
-
资助金额:$24.11万
-
财政年份:2004
-
负责人:John A. Copland
-
依托单位:
TGF Beta receptor biology in human renal cell carcinoma
-
批准号:7426896
-
项目类别:
-
资助金额:$22.89万
-
财政年份:2004
-
负责人:John A. Copland
-
依托单位:
TGF Beta receptor biology in human renal cell carcinoma
-
批准号:7238659
-
项目类别:
-
资助金额:$23.08万
-
财政年份:2004
-
负责人:John A. Copland
-
依托单位:
海外基金